Active, not recruitingPhase 3NCT05949684
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Studying Myelodysplastic neoplasm with increased blasts
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- Luspatercept(biological)
- Enrollment
- 360 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2030
Study locations (30)
- Local Institution - 0070, Clovis, California, United States
- Local Institution - 0179, Fountain Valley, California, United States
- Local Institution - 0211, Los Alamitos, California, United States
- Local Institution - 0258, Los Angeles, California, United States
- Local Institution - 0247, Orange, California, United States
- Local Institution - 0209, Oxnard, California, United States
- Local Institution - 0183, Walnut Creek, California, United States
- Local Institution - 0227, Hartford, Connecticut, United States
- Local Institution - 0173, New Haven, Connecticut, United States
- Halifax Health Medical Center, Daytona Beach, Florida, United States
- Local Institution - 0202, Fort Myers, Florida, United States
- Local Institution - 0180, Jacksonville, Florida, United States
- Local Institution - 0224, Margate, Florida, United States
- Local Institution - 0163, Plantation, Florida, United States
- Local Institution - 0201, St. Petersburg, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05949684 on ClinicalTrials.govOther trials for Myelodysplastic neoplasm with increased blasts
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07511829WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing TreatmentUniversity of Oxford
- RECRUITINGPHASE2NCT06717958Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) MutationTechnische Universität Dresden
- RECRUITINGPHASE3NCT06499285A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsTakeda
- RECRUITINGPHASE1NCT06616636A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)M.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06138587Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05782127Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic SyndromesGroupe Francophone des Myelodysplasies
- ACTIVE NOT RECRUITINGPHASE2NCT04994808Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid LeukemiaFred Hutchinson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT05379166Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic SyndromeUma Borate
See all trials for Myelodysplastic neoplasm with increased blasts →